ES2668967T3 - Inmunógenos de Escherichia coli con solubilidad mejorada - Google Patents
Inmunógenos de Escherichia coli con solubilidad mejorada Download PDFInfo
- Publication number
- ES2668967T3 ES2668967T3 ES09712707T ES09712707T ES2668967T3 ES 2668967 T3 ES2668967 T3 ES 2668967T3 ES 09712707 T ES09712707 T ES 09712707T ES 09712707 T ES09712707 T ES 09712707T ES 2668967 T3 ES2668967 T3 ES 2668967T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- nos
- escherichia coli
- enhanced solubility
- immunogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000588724 Escherichia coli Species 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un polipéptido que comprende una secuencia de aminoácidos que: (a) es idéntica a una cualquiera de las SEQ ID NOs: 5 a 16; (b) tiene de 1 a 10 alteraciones de un solo aminoácido en comparación con (a); (c) tiene al menos un 95 % de identidad de secuencia con una cualquiera de las SEQ ID NOs: 5 a 16; y/o (d) es un fragmento de al menos 250 aminoácidos consecutivos de cualquiera de las SEQ ID NOs: 5 a 16; o (e) tiene al menos un 95 % de identidad con cualquiera de las SEQ ID NOs: 5 a 16 y comprende un fragmento de al menos 10 aminoácidos consecutivos de cualquiera de las SEQ ID NOs: 5 a 16; con la condición de que dicha secuencia de aminoácidos no sea la SEQ ID NO: 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3090208P | 2008-02-22 | 2008-02-22 | |
| IT001249A ITMI20081249A1 (it) | 2008-07-09 | 2008-07-09 | Immunogeni di escherichia coli con solubilità migliorata. |
| PCT/IB2009/000440 WO2009104092A2 (en) | 2008-02-22 | 2009-02-23 | Escherichia coli immunogens with improved solubility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2668967T3 true ES2668967T3 (es) | 2018-05-23 |
Family
ID=40873250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09712707T Active ES2668967T3 (es) | 2008-02-22 | 2009-02-23 | Inmunógenos de Escherichia coli con solubilidad mejorada |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8470341B2 (es) |
| EP (1) | EP2254903B1 (es) |
| JP (1) | JP2011512152A (es) |
| AU (1) | AU2009215359A1 (es) |
| CA (1) | CA2716210A1 (es) |
| ES (1) | ES2668967T3 (es) |
| IT (1) | ITMI20081249A1 (es) |
| TR (1) | TR201807673T4 (es) |
| WO (1) | WO2009104092A2 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| ITMI20090946A1 (it) * | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
| CA2768343A1 (en) * | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
| AU2010288239B2 (en) | 2009-08-27 | 2014-01-16 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
| EP2519265B1 (en) * | 2009-12-30 | 2018-11-14 | GlaxoSmithKline Biologicals SA | Polysaccharide immunogens conjugated to e. coli carrier proteins |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| US10286056B2 (en) | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| PT2750707T (pt) | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| US9511130B2 (en) | 2011-09-14 | 2016-12-06 | Glaxosmithkline Biologicals Sa | Escherichia coli vaccine combination |
| AU2013320313B2 (en) | 2012-09-18 | 2018-07-12 | Glaxosmithkline Biologicals Sa | Outer membrane vesicles |
| WO2014102694A1 (en) | 2012-12-24 | 2014-07-03 | Novartis Ag | Novel mucinase for use in therapy or prophylaxis |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP2976965A1 (en) | 2014-07-22 | 2016-01-27 | Braun GmbH | Fastenable device for oral cavity position detection |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| EP3153519A1 (en) * | 2015-10-06 | 2017-04-12 | Syddansk Universitet | Glycosylated yghj polypeptides from enterotoxigenic escherichia coli (etec) |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| US20250134824A1 (en) | 2021-08-16 | 2025-05-01 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
| US20260124157A1 (en) | 2024-08-09 | 2026-05-07 | Genvax Technologies, Inc. | Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994012529A1 (en) * | 1992-12-03 | 1994-06-09 | The Regents Of The University Of California | Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome |
| AU2006214064B2 (en) * | 2005-02-18 | 2012-04-26 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| JP2006296420A (ja) * | 2005-03-22 | 2006-11-02 | Nippon Shokubai Co Ltd | 親水性ジオールデヒドラターゼ及び疎水性グリセロールデヒドラターゼを製造する方法 |
-
2008
- 2008-07-09 IT IT001249A patent/ITMI20081249A1/it unknown
-
2009
- 2009-02-23 WO PCT/IB2009/000440 patent/WO2009104092A2/en not_active Ceased
- 2009-02-23 ES ES09712707T patent/ES2668967T3/es active Active
- 2009-02-23 US US12/735,848 patent/US8470341B2/en active Active
- 2009-02-23 CA CA2716210A patent/CA2716210A1/en not_active Abandoned
- 2009-02-23 EP EP09712707.0A patent/EP2254903B1/en active Active
- 2009-02-23 AU AU2009215359A patent/AU2009215359A1/en not_active Abandoned
- 2009-02-23 JP JP2010547267A patent/JP2011512152A/ja not_active Withdrawn
- 2009-02-23 TR TR2018/07673T patent/TR201807673T4/tr unknown
-
2013
- 2013-05-29 US US13/904,855 patent/US9101560B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009215359A1 (en) | 2009-08-27 |
| US8470341B2 (en) | 2013-06-25 |
| CA2716210A1 (en) | 2009-08-27 |
| US9101560B2 (en) | 2015-08-11 |
| US20130323274A1 (en) | 2013-12-05 |
| ITMI20081249A1 (it) | 2010-01-09 |
| US20110091492A1 (en) | 2011-04-21 |
| JP2011512152A (ja) | 2011-04-21 |
| EP2254903A2 (en) | 2010-12-01 |
| WO2009104092A3 (en) | 2010-02-25 |
| WO2009104092A2 (en) | 2009-08-27 |
| EP2254903B1 (en) | 2018-03-21 |
| TR201807673T4 (tr) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| ES2539812T3 (es) | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| ES2691539T3 (es) | Luciferasas de Oplophorus sintéticas con mayor emisión de luz | |
| ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
| IN2014CN02050A (es) | ||
| EA201390820A1 (ru) | Слитый белок против рака | |
| MX359680B (es) | Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores. | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| ES2531115T3 (es) | Combinaciones de clados de RrgB neumocócicos | |
| EA201000327A1 (ru) | Белок | |
| CO6491059A2 (es) | Diferenciacion de las celulas madre mesenquimales | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| EA200901441A1 (ru) | Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90 | |
| EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
| MX2021002295A (es) | Variantes de proteinas recombinantes. | |
| DE60335726D1 (de) | Chromoprotein und fluoroproteine | |
| CY1111630T1 (el) | Παραγωγα κυτοκινων | |
| WO2010057242A3 (de) | Vakzin | |
| EA201391546A1 (ru) | Противораковый слитый белок | |
| ES2609586T3 (es) | Secuencias de nucleótidos y aminoácidos que codifican una proteína exportada 1 derivada de Plasmodium vivax y usos de las mismas | |
| ES2536238T3 (es) | Péptidos antimicrobianos | |
| WO2019103512A3 (ko) | 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질 |